QuickLinks -- Click here to rapidly navigate through this document

Exhibit 12

E. I. DU PONT DE NEMOURS AND COMPANY

COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES
(Dollars in millions)

		Years Ended December 31
		2005			2004			2003			2002			2001
Income from Continuing Operations
	Before Extraordinary Item and Cumulative Effect of a Change In Accounting Principles	$	2,053		$	1,780		$	1,002		$	1,841		$	4,328	(a)
Provision for (Benefit from) Income Taxes			1,468			(329	)		(930	)		185			2,467
Minority Interests in Earnings (Losses) of Consolidated Subsidiaries			37			(9	)		71			98			49
Adjustment for Companies Accounted for by the Equity Method			215			99			360			45			93
Capitalized Interest			(23	)		(17	)		(29	)		(45	)		(62	)
Amortization of Capitalized Interest			33			365	(b)		119	(b)		59			61
			3,783			1,889			593			2,183			6,936
Fixed Charges:
	Interest and Debt Expense		518			362			347			359			590
	Capitalized Interest		23			17			29			45			62
	Rental Expense Representative of Interest Factor		88			91			90			82			78
			629			470			466			486			730
Total Adjusted Earnings Available for Payment of Fixed Charges		$	4,412		$	2,359		$	1,059		$	2,669		$	7,666
Number of Times Fixed Charges are Earned			7.0			5.0			2.3			5.5			10.5

(a)

Includes $3,866 after-tax gain on the sale of DuPont Pharmaceuticals to Bristol-Myers Squibb.

(b)

Includes write-off of capitalized interest associated with exiting certain businesses.

QuickLinks

Exhibit 12